Dynasil Corporation of America (DYSL) 10-Q 12 Feb 14 2014 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Dec. 31, 2013	Feb. 06, 2014
Document Information [Line Items]	'	'
Entity Registrant Name	'DYNASIL CORP OF AMERICA	'
Entity Central Index Key	'0000030831	'
Current Fiscal Year End Date	'--09-30	'
Entity Filer Category	'Smaller Reporting Company	'
Trading Symbol	'DYSL	'
Entity Common Stock, Shares Outstanding	'	15,506,303
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Dec-13	'
Document Fiscal Period Focus	'Q1	'
Document Fiscal Year Focus	'2014	'

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2013	Sep. 30, 2013
Current Assets	'	'
Cash and cash equivalents	$2,755,356	$2,436,828
Accounts receivable, net of allowances of $338,740 and $184,775 at December 31, 2013 and September 30, 2013, respectively	2,633,601	3,657,320
Costs in excess of billings and unbilled receivables	2,292,809	1,537,318
Inventories, net of reserves	2,678,524	3,140,244
Prepaid expenses and other current assets	1,509,878	1,291,942
Total current assets	11,870,168	12,063,652
Property, Plant and Equipment, net	4,568,183	4,773,779
Other Assets	'	'
Intangibles, net	1,357,492	3,484,583
Goodwill	6,256,323	6,240,983
Deferred financing costs, net	103,137	114,229
Total other assets	7,716,952	9,839,795
Total Assets	24,155,303	26,677,226
Current Liabilities	'	'
Current portion of long-term debt	5,429,762	9,819,048
Capital lease obligations, current	124,383	124,383
Accounts payable	2,045,238	2,056,262
Deferred revenue	347,688	515,790
Accrued expenses and other liabilities	2,875,923	2,846,850
Total current liabilities	10,822,994	15,362,333
Long-term Liabilities	'	'
Capital lease obligations, net of current portion	269,490	232,173
Convertible notes	378,461	0
Pension liability	249,966	249,966
Deferred tax liability	183,417	186,866
Total long-term liabilities	1,081,334	669,005
Stockholders' Equity	'	'
Common Stock, $0.0005 par value, 40,000,000 shares authorized, 16,274,274 and 16,224,402 shares issued, 15,464,114 and and 15,414,242 shares outstanding at December 31, 2013 and September 30, 2013, respectively.	8,137	8,112
Additional paid in capital	17,599,418	17,476,003
Accumulated other comprehensive income	188,849	152,685
Accumulated deficit	-4,546,900	-6,004,570
Less 810,160 shares of treasury stock - at cost	-986,342	-986,342
Total Dynasil stockholders' equity	12,263,162	10,645,888
Noncontrolling interest	-12,187	0
Total stockholders' equity	12,250,975	10,645,888
Total Liabilities and Stockholders' Equity	$24,155,303	$26,677,226

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS [Parenthetical] (USD $)	Dec. 31, 2013	Sep. 30, 2013
Allowance for doubtful accounts (in dollars)	$338,740	$184,775
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	40,000,000	40,000,000
Common stock, shares issued	16,274,274	16,224,402
Common stock, shares outstanding	15,464,114	15,414,242
Treasury stock, shares	810,160	810,160

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (USD $)	3 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Net revenue	$10,711,528	$10,553,275
Cost of revenue	6,261,000	5,926,409
Gross profit	4,450,528	4,626,866
Operating expenses:	'	'
Sales and marketing expenses	396,805	479,878
Research and development expenses	346,197	637,129
General and administrative expenses	3,279,999	3,788,949
Total operating expenses	4,023,001	4,905,956
Gain on sale of assets	1,186,691	87,803
Income (loss) from operations	1,614,218	-191,287
Interest expense, net	212,778	186,757
Income (loss) before taxes	1,401,440	-378,044
Income tax (credit) provision	-44,043	1,298
Net income (loss)	1,445,483	-379,342
Less: Net loss attributable to noncontrolling interest	-12,187	0
Net income (loss) attributable to common stockholders	1,457,670	-379,342
Net income (loss)	1,445,483	-379,342
Other comprehensive income (loss):	'	'
Foreign currency translation	36,164	29,739
Total comprehensive income (loss)	$1,481,647	($349,603)
Basic net income (loss) per common share ( in dollars per share)	$0.10	($0.03)
Diluted net income (loss) per common share (in dollars per share)	$0.10	($0.03)
Weighted average shares outstanding	'	'
Basic (in shares)	15,021,757	14,673,356
Diluted (in shares)	15,281,841	14,673,356

CONSOLIDATED_STATEMENTS_OF_CHA

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Retained Earnings [Member]	Treasury Stock [Member]	Noncontrolling Interest [Member]
Balance at Sep. 30, 2013	$10,645,888	$8,112	$17,476,003	$152,685	($6,004,570)	($986,342)	$0
Balance (in shares) at Sep. 30, 2013	'	16,224,402	'	'	'	810,160	'
Issuance of shares of common stock under employee stock purchase plan	4,464	2	4,462	0	0	0	0
Issuance of shares of common stock under employee stock purchase plan (in shares)	'	3,848	'	'	'	0	'
Stock-based compensation costs	118,976	23	118,953	0	0	0	0
Stock-based compensation costs (in shares)	'	46,024	'	'	'	0	'
Foreign currency translation adjustment	36,164	0	0	36,164	0	0	0
Net income (loss)	1,445,483	0	0	0	1,457,670	0	-12,187
Balance at Dec. 31, 2013	$12,250,975	$8,137	$17,599,418	$188,849	($4,546,900)	($986,342)	($12,187)
Balance (in shares) at Dec. 31, 2013	'	16,274,274	'	'	'	810,160	'

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:	'	'
Net income (loss)	$1,445,483	($379,342)
Adjustments to reconcile net income (loss) to net cash:	'	'
Stock compensation expense	119,646	73,516
Foreign exchange loss	6,868	26,398
Gain on sale of assets	-1,186,691	-87,803
Depreciation and amortization	266,325	426,458
Other	11,970	28,707
Other changes in assets and libilities:	'	'
Accounts receivable, net	600,153	607,217
Inventories	-224,502	-322,298
Costs in excess of billings and unbilled receivables	-755,491	-205,749
Prepaid expenses and other assets	-219,403	-76,842
Accounts payable	-8,567	399,184
Accrued expenses and other liabilities	273,836	-852,463
Deferred revenue	-166,609	140,355
Net cash provided by (used in) operating activities	163,018	-222,662
Cash flows from investing activities:	'	'
Proceeds from sale of assets	4,357,219	80,252
Purchases of property, plant and equipment	-130,918	-315,568
Net cash provided by (used in) investing activities	4,226,301	-235,316
Cash flows from financing activities:	'	'
Proceeds from issuance of common stock	3,794	6,110
Payment of debt issuance costs	-1,715	0
Net proceeds from issuance of convertible notes	378,461	0
Principal payments on capital leases	-29,864	0
Payments on long-term debt	-4,389,286	-472,587
Net cash used in financing activities	-4,038,610	-466,477
Effect of exchange rates on cash and cash equivalents	-32,181	-18,525
Net increase (decrease) in cash and cash equivalents	318,528	-942,980
Cash and cash equivalents, beginning	2,436,828	3,414,880
Cash and cash equivalents, ending	2,755,356	2,471,900
Non cash activities:	'	'
Assets purchased under capital leases	$67,181	$0

Basis_of_Presentation_and_Abil

Basis of Presentation and Ability to Continue as a Going Concern	3 Months Ended
	Dec. 31, 2013
Disclosure Text Block [Abstract]	'
Nature of Operations [Text Block]	'
	Note 1 - Basis of Presentation and Ability to Continue as a Going Concern
	The accompanying consolidated balance sheet as of December 31, 2013, the consolidated statements of operations and comprehensive income (loss) for the three months ended December 31, 2013 and 2012, changes in stockholders’ equity for the three months ended December 31, 2013 and cash flows for the three months ended December 31, 2013 and 2012 of Dynasil Corporation of America and subsidiaries (the “Company”), and the related information contained in these notes have been prepared by management and are unaudited. In the opinion of management, all adjustments (which include normal recurring and nonrecurring items) necessary to present fairly the financial position, results of operations and cash flows in conformity with generally accepted accounting principles for the periods presented have been made.  Interim operating results are not necessarily indicative of operating results for a full year.
	The preparation of our unaudited consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods.  Certain information and note disclosures normally included in the Company's annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted.  These consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company's September 30, 2013 Annual Report on Form 10-K previously filed by the Company with the Securities and Exchange Commission.
	The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplates continuation of the Company as a going concern. However, the Company failed to comply with the financial covenants set forth in the terms of its outstanding loan agreements and sustained substantial losses from operations for the years ended September 30, 2013 and 2012.
	Although the Company returned to profitability for the three months ended December 31, 2013 and is in compliance with the debt covenants included in its senior loan agreement as of December 31, 2013, it remains in default due to its violation of certain covenants for prior periods, as described below.  Additionally, at the request of its senior lender, it has not paid interest due to its subordinated lender since February 2013 in the amount of approximately $400,000.  Nonpayment of interest when due is a separate event of default under its loan agreements.  In addition, the Company has not obtained waivers from either of its lenders for its prior covenant defaults.
	The Company was in default of the financial covenants set forth in the terms of its loan agreements for its fiscal quarter ended September 30, 2012, and for each quarter in fiscal 2013. These covenants require the Company to maintain specified ratios of earnings before interest, taxes, depreciation and amortization (EBITDA) to fixed charges and to total/senior debt.  A default gives the lenders the right to accelerate the maturity of the outstanding indebtedness and foreclose on any security interest. To date, the lenders have not taken any such actions. Until such time as the Company is able to resolve its covenant defaults, there will be substantial doubt over the Company’s ability to continue as a going concern.
	While the Company is currently in negotiations with its senior and subordinated lenders and expects to resolve its current and prior covenant defaults, there can be no assurance as to whether or when it will do so.
	Until the covenant violations are waived or otherwise resolved, the debt remains subject to acceleration by the lenders.  Consequently, the Company continues to classify all of its outstanding indebtedness as a current liability in the accompanying consolidated balance sheets.
	The Company has recently taken a number of actions to improve its liquidity, including the sale of its lead paint detection and medical instruments businesses which resulted in additional principal payments to its senior lender of $3.9 million in the first quarter ended December 31, 2013.  The Company also made an additional payment of $300,000 to its senior lender in August 2013 in connection with amendments to its loan agreements which permitted the Company to contribute certain assets of its Biomedical business to a joint venture and to exclude the results of the start-up joint venture from its loan covenants.
	As a result of these payments and its regular monthly principal payments, the Company’s outstanding debt has been reduced to $5.4 million at December 31, 2013 from $11.5 million at December 31, 2012.  Nevertheless, the Company does not currently have cash available to satisfy its remaining obligations under its indebtedness if they were to be accelerated and payment was demanded.  If the Company is not able to resolve its current defaults under its outstanding indebtedness, it may not have sufficient liquidity to meet its anticipated cash needs for the next twelve months.
	The Company considers events or transactions that have occurred after the unaudited consolidated balance sheet date of December 31, 2013, but prior to the filing of the unaudited consolidated financial statements with the SEC on this Form 10-Q, to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure, as applicable. Subsequent events have been evaluated through the date of the filing of this Quarterly Report on Form 10-Q with the SEC.

Businesses_Sold

Businesses Sold	3 Months Ended
	Dec. 31, 2013
Businesses Sold [Abstract]	'
Businesses Sold [Text Block]	'
	Note 2 – Businesses Sold
	In the first quarter of 2014, the Company sold its lead paint detection and medical instruments businesses which comprised substantially all operating assets of its Instruments segment.
	On November 7, 2013, the Company sold its Lead Paint detector business to Protec Instrument Corporation (“Protec”), a wholly owned subsidiary of Laboratoires Protec S.A., a French corporation and former European distributor of the Company’s lead paint detector products. The sales price totaled approximately $1.2 million, including the assumption of certain liabilities by Protec.  The transaction also resulted in payment to the Company of approximately $0.5 million in satisfaction of outstanding accounts receivable. Concurrently with the sale, the Company and Protec entered into a transition services agreement pursuant to which the Company will provide certain transitional services to Protec for up to five months after closing.  The Company used $1.175 million of the proceeds from the sale to reduce its indebtedness to Santander Bank, N.A.
	On December 23, 2013, the Company sold its Gamma Medical Probe business to Dilon Technologies, Inc., a Delaware corporation (“Dilon”), for $3.5 million, the assumption of certain liabilities of the Company, and a possible contingent payment.  The Agreement also provided for $250,000 of the proceeds to be deposited in escrow for a year, which amount is included in accounts receivable in the Consolidated Balance Sheet.  The Asset Purchase Agreement (“Agreement”) contains customary representations, warranties, covenants and indemnification provisions.  Concurrently with the sale, the Company and Dilon entered into a transition services agreement pursuant to which the Company will provide certain transitional services to Dilon for up to five months after closing.  The Company used $2.75 million of the proceeds from the sale to reduce its indebtedness to Santander Bank, N.A.
	In connection with the sales of the businesses discussed above, the Company recorded a gain of $1.2 million which is included in Income from Operations in the three months ended December 31, 2013.  The businesses sold constituted substantially all of Instruments segment but did not constitute a component of the business, and therefore did not qualify to be reported as discontinued operations. The assets held for sale at September 30, 2013 included fixed assets, inventory, and intangible customer assets totaling $2.9 million offset by customer deposits of approximately $100,000.

Formation_of컞Technologie

Formation of Xcede Technologies, Inc. Joint Venture	3 Months Ended
	Dec. 31, 2013
Equity Method Investments and Joint Ventures [Abstract]	'
Equity Method Investments and Joint Ventures Disclosure [Text Block]	'
	Note 3 – Formation of Xcede Technologies, Inc. Joint Venture
	On or about October 1, 2013, the Company formed Xcede Technologies, Inc. (“Xcede”), a joint venture with Mayo Clinic, in order to spin out and separately fund the development of its tissue sealant technology which formerly comprised the majority of its Biomedical segment. Xcede has initiated financing efforts and has received approximately $400,000 in funding in the form of Convertible Notes from outside investors including certain directors of the Company.  The notes accrue interest at 5%.  Upon the closing of a capital stock financing, the outstanding principal amount of the notes plus all accrued but unpaid interest on the notes will be converted into shares of the same capital stock sold in the capital stock financing at a 20% discount to the price per share of that capital stock financing.  Alternatively, at any time prior to a capital stock financing the note holders can convert at their option into common stock based on a $5 million valuation.
	Xcede is continuing its fund raising efforts as it will require additional funding in connection with human trials expected to commence in the third quarter of 2014.
	Xcede is 90% owned by Dynasil Biomedical and, as a result, is included in the Company’s consolidated balance sheet, results of operations and cash flows. Dynasil Biomedical holds a majority of the seats on Xcede’s board of directors.

Inventories

Inventories	3 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Inventory Disclosure [Text Block]	'
	Note 4 - Inventories
	Inventories, net of reserves, consists of the following:
		December 31,		September 30,
		2013		2013
	Raw Materials	$	1,713,898	$	2,132,962
	Work-in-Process		717,888		703,873
	Finished Goods		246,738		303,409
		$	2,678,524	$	3,140,244

Intangible_Assets

Intangible Assets	3 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangible Assets Disclosure [Text Block]	'
	Note 5 – Intangible Assets
	Intangible assets at December 31, 2013 and September 30, 2013 consist of the following:
		Useful		Gross			Accumulated
	31-Dec-13	Life (years)		Amount			Amortization			Net
	Acquired Customer Base	5 to 15		$	881,075		$	352,659		$	528,416
	Know How	15			512,000			187,815			324,185
	Trade Names	Indefinite			341,558			-			341,558
	Biomedical Technologies	2.25 - 5			260,000			96,667			163,333
				$	1,994,633		$	637,141		$	1,357,492
		Useful		Gross			Accumulated
	30-Sep-13	Life (years)		Amount			Amortization			Net
	Acquired Customer Base	5 to 15		$	5,145,638		$	2,645,715		$	2,499,923
	Know How	15			512,000			179,283			332,717
	Trade Names	15 or Indefinite			547,802			75,856			471,946
	Biomedical Technologies	5			300,000			120,003			179,997
				$	6,505,440		$	3,020,857		$	3,484,583
	Amortization expense for the three months ended December 31, 2013 and 2012 was $44,888 and $181,268, respectively.  Estimated amortization expense for each of the next five fiscal years is as follows:
		2014			2015			2016			2017		2018		Thereafter		Total
	Acquired Customer Base	$	59,964		$	79,952		$	79,952		$	79,952	$	79,952	$	148,644	$	528,416
	Know How		25,596			34,128			34,128			34,128		34,128		162,077		324,185
	Biomedical Technologies		50,000			66,667			46,666			-		-		-		163,333
		$	135,560		$	180,747		$	160,746		$	114,080	$	114,080	$	310,721	$	1,015,934

Goodwill

Goodwill	3 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill Disclosure [Text Block]	'
	Note 6 – Goodwill
	Goodwill is subject to an annual impairment test.  The Company considers many factors which may indicate the requirement to perform additional, interim impairment tests.  These include:
		·	A significant adverse long term outlook for any of its industries;
		·	An adverse finding or rejection from a regulatory body involved in new product regulatory approvals;
		·	Failure of an anticipated commercialization of a product or product line;
		·	Unanticipated competition or the introduction of a disruptive technology;
		·	The testing for recoverability under the Impairment or Disposal of Long-Lived Assets Subsections of Subtopic 360-10 of a significant asset group within a reporting unit;
		·	A loss of key personnel; and
		·	An expectation that a reporting unit carrying goodwill, or a significant portion of a reporting unit, will be sold or otherwise disposed of.
	There were no changes, aside from foreign exchange rate fluctuations, in the carrying value of goodwill during the three months ended December 31, 2013.

Earnings_Loss_Per_Common_Share

Earnings (Loss) Per Common Share	3 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	Note 7 – Earnings (Loss) Per Common Share
	Basic earnings (loss) per common share is computed by dividing the net income applicable or loss attributable to common shares by the weighted average number of common shares.  Diluted earnings per common share adjusts basic earnings per share for the effects of common stock options, common stock warrants, convertible preferred stock and other potential dilutive common shares outstanding during the periods.
	For purposes of computing diluted earnings per share for the three months ended December 31, 2013 and 2012, no common stock options were included in the calculation of dilutive shares as all of the 630,532 and 774,483 common stock options outstanding, respectively, had exercise prices above the current quarterly average market price per share and their inclusion is anti-dilutive.  Additionally, for the three months ended December 31, 2012, no common share equivalents related to stock options or unvested restricted stock were included in the calculation of dilutive shares, since there was a loss from continuing operations and the inclusion of common share equivalents would be anti-dilutive.
	The computation of the weighted shares outstanding for the three months ended December 31 is as follows:
		December 31, 2013		December 31, 2012
	Weighted average shares outstanding
	Basic		15,021,757		14,673,356
	Effect of dilutive securities
	Stock Options		-		-
	Restricted Stock		260,084		-
	Dilutive Average Shares Outstanding		15,281,841		14,673,356

Stock_Based_Compensation

Stock Based Compensation	3 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	Note 8 - Stock Based Compensation
	The fair value of the stock options granted is estimated at the date of grant using the Black-Scholes option pricing model.
	A summary of stock option activity for the three months ended December 31, 2013 and 2012 is presented below:
				Weighted Average		Weighted Average
		Options		Exercise Price per		Remain Contractual
		Outstanding		Share		Term (in Years)
	Balance at September 30, 2013		630,532	$	3.33	1.06
	Outstanding and exercisable at September 30, 2013		630,532	$	3.33	1.06
	Granted		-		-
	Exercised		-		-
	Cancelled		-		-
	Balance at December 31, 2013		630,532	$	3.33	0.81
	Outstanding and exercisable at December 31, 2013		630,532	$	3.33	0.81
				Weighted Average		Weighted Average
		Options		Exercise Price per		Remain Contractual
		Outstanding		Share		Term (in Years)
	Balance at September 30, 2012		794,483	$	3.34	1.75
	Outstanding and exercisable at September 30, 2012		794,483	$	3.34	1.75
	Granted		-		-
	Exercised		-		-
	Cancelled		-20,000	$	4.06
	Balance at December 31, 2012		774,483	$	3.32	1.54
	Outstanding and exercisable at December 31, 2012		774,483	$	3.32	1.54
	A summary of restricted stock activity for the three months ended December 31, 2013 and 2012 is presented below:
	Restricted Stock Activity for the Three			Weighted-Average
	Months ended December 31, 2013	Shares		Grant-Date Fair Value
	Nonvested at September 30, 2013		423,168	$	0.74
	Granted		-	$	-
	Vested		-12,500	$	1.08
	Cancelled		-	$	-
	Nonvested at December 31, 2013		410,668	$	0.73
	Restricted Stock Activity for the Three			Weighted-Average
	Months ended December 31, 2012	Shares		Grant-Date Fair Value
	Nonvested at September 30, 2012		127,834	$	1.92
	Granted		4,000	$	1.45
	Vested		-15,000	$	1.53
	Cancelled		-	$	-
	Nonvested at December 31, 2012		116,834	$	1.95
	Stock Compensation Expense for the three months ended December 31, 2013 and 2012 is as follows:
		Three Months Ended		Three Months Ended
	Stock Compensation Expense	December 31, 2013		December 31, 2012
	Stock Grants	$	50,626	$	52,461
	Restricted Stock Grants		68,351		12,618
	Option Grants		-		7,359
	Employee Stock Purchase Plan		669		1,078
	Total	$	119,646	$	73,516
	At December 31, 2013 there was approximately $170,000 in unrecognized stock compensation cost, which is expected to be recognized over a weighted average period of five months.

Segment_Customer_and_Geographi

Segment, Customer and Geographical Reporting	3 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Segment Reporting Disclosure [Text Block]	'
	Note 9 – Segment, Customer and Geographical Reporting
	Segment Financial Information
	Dynasil’s business is comprised of four segments: contract research (“Contract Research”), optics (“Optics”), instruments (“Instruments”) and biomedical (“Biomedical”).   Within these segments, there is a segregation of reportable units based upon the organizational structure used to evaluate performance and make decisions on resource allocation, as well as availability and materiality of separate financial results consistent with that structure. The Contract Research segment is one of the largest small business participants in U.S. government-funded research.  The Optics segment manufactures optical materials, components and coatings.  The Instruments segment manufactures specialized instruments used in various applications in the medical, industrial, and homeland security/defense sectors. The Biomedical segment, through Xcede Technologies, Inc., a majority owned, joint venture (“Xcede”), is focused on developing a tissue sealant technology for a wide spectrum of applications though no assurance can be given that this technology will become successfully commercialized.
	As discussed in Note 2, substantially all the operating assets of the Instruments segment were sold in the three months ended December 31, 2013.
	The Company’s segment information for the three months ended December 31, 2013 and 2012 is summarized below:
	Results of Operations for the Three Months Ended December 31,
	2013
		Contract
		Research		Optics		Instruments		Biomedical		Total
	Revenue	$	5,840,442	$	4,098,508	$	772,578	$	-	$	10,711,528
	Gross Profit		2,529,539		1,597,259		323,730		-		4,450,528
	Operating Income (Loss)		348,394		398,428		1,041,768		-174,372		1,614,218
	Depreciation and Amortization		69,547		178,108		2,003		16,667		266,325
	Capital expenditures		-		130,918		-		-		130,918
	Intangibles, Net		324,185		869,974		-		163,333		1,357,492
	Goodwill		4,938,625		1,317,698		-		-		6,256,323
	Total Assets	$	10,359,612	$	12,538,356	$	752,431	$	504,904	$	24,155,303
	Results of Operations for the Three Months Ended December 31,
	2012
		Contract
		Research		Optics		Instruments		Biomedical		Total
	Revenue	$	4,910,840	$	4,251,940	$	1,284,038	$	106,457	$	10,553,275
	Gross Profit		2,214,053		1,700,555		605,801		106,457		4,626,866
	Operating Income (Loss)		-606		385,676		-455,694		-120,663		-191,287
	Depreciation and Amortization		62,782		185,628		163,048		15,000		426,458
	Capital expenditures		186,330		122,146		7,092		-		315,568
	Intangibles, Net		339,886		946,525		5,016,201		224,996		6,527,608
	Goodwill		4,938,625		1,310,802		4,015,072		-		10,264,499
	Total Assets	$	13,290,669	$	10,607,828	$	12,092,507	$	388,671	$	36,379,675
	Customer Financial Information
	For the three months ended December 31, 2013 and 2012, the top three customers for the Contract Research segment were various agencies of the U.S. Government.  For the three months ended December 31, 2013 and 2012, these customers made up 64% and 68%, respectively, of Contract Research revenue.
	For the three months ended December 31, 2013 and 2012, there was no customer in the Optics segment whose revenue represented more than 10% of the total segment revenue for the three months ended December 31, 2013 and 2012.
	For the three months ended December 31, 2013 and 2012, the top three customers for the Instruments segment made up 24% and 40%, respectively, of Instruments revenue.
	For the three months ended December 31, 2012, the Biomedical segment had two customers whose revenue represented 100% of the total segment revenue.  There was no revenue for the three months ended December 31, 2013.
	Geographic Financial Information
	Revenue by geographic location in total and as a percentage of total revenue, for the three months ended December 31, 2013 and 2012 are as follows:
		Three Months Ended				Three Months Ended
		December 31, 2013				December 31, 2012
	Geographic Location	Revenue		% of Total		Revenue		% of Total
	United States	$	8,907,730	83	%	$	8,494,488	81	%
	Europe		829,437	8	%		888,341	8	%
	Other		974,361	9	%		1,170,446	11	%
		$	10,711,528	100	%	$	10,553,275	100	%

Income_Taxes

Income Taxes	3 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	Note 10 - Income Taxes
	Dynasil Corporation of America and its wholly-owned U.S. subsidiaries file a consolidated federal income tax return and various state returns.  The Company’s U.K. subsidiary files tax returns in the U.K.
	The Company uses the asset and liability approach to account for income taxes.  Under this approach, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and net operating loss and tax credit carry forwards.  The amount of deferred taxes on these temporary differences is determined using the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, as applicable, based on tax rates, and tax laws, in the respective tax jurisdiction then in effect.
	In assessing the ability to realize the net deferred tax assets, management considers various factors including taxable income in carryback years, future reversals of existing taxable temporary differences, tax planning strategies and projections of future taxable income, to determine whether it is more likely than not that some portion or all of the net deferred tax assets will not be realized. Based upon the Company’s recent losses and uncertainty of future profits, the Company has determined that the uncertainty regarding the realization of these assets is sufficient to warrant the need for a full valuation allowance against its U.S. net deferred tax assets.
	The Company applies the authoritative provisions related to accounting for uncertainty in income taxes.  As required by these provisions, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more-likely-than-not sustain the position following an audit.  For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being reached upon ultimate settlement with the relevant tax authority.  As of December 31, 2013 and September 30, 2013, the Company has no unrecorded liabilities for uncertain tax positions.  Interest and penalty charges, if any, related to uncertain tax positions would be classified as income tax expense in the accompanying consolidated statement of operations.  As of December 31, 2013 and September 30, 2013, the Company had no accrued interest or penalties related to uncertain tax positions.  The Company currently has no federal or state tax examinations in progress.
	The effective rate of (3.12%) for the three months ended December 31, 2013 and (0.34%) for the three months ended December 31, 2012 differs from the U.S. federal statutory income tax rate of 34% primarily due to a full valuation allowance against the Company’s U.S. deferred tax asset.
	The Company files its tax returns as prescribed by the tax laws of the jurisdictions in which it operates.  The Company’s tax filings for federal and state jurisdictions for the tax years beginning with 2010 are still subject to examination.

Subsequent_Events

Subsequent Events	3 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	Note 11 – Subsequent Events
	The Company has evaluated subsequent events through the date that the financial statements were released.

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Schedule of Inventory, Current [Table Text Block]	'
	Inventories, net of reserves, consists of the following:
		December 31,		September 30,
		2013		2013
	Raw Materials	$	1,713,898	$	2,132,962
	Work-in-Process		717,888		703,873
	Finished Goods		246,738		303,409
		$	2,678,524	$	3,140,244

Intangible_Assets_Tables

Intangible Assets (Tables)	3 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Finite-Lived Intangible Assets [Table Text Block]	'
	Intangible assets at December 31, 2013 and September 30, 2013 consist of the following:
		Useful		Gross			Accumulated
	31-Dec-13	Life (years)		Amount			Amortization			Net
	Acquired Customer Base	5 to 15		$	881,075		$	352,659		$	528,416
	Know How	15			512,000			187,815			324,185
	Trade Names	Indefinite			341,558			-			341,558
	Biomedical Technologies	2.25 - 5			260,000			96,667			163,333
				$	1,994,633		$	637,141		$	1,357,492
		Useful		Gross			Accumulated
	30-Sep-13	Life (years)		Amount			Amortization			Net
	Acquired Customer Base	5 to 15		$	5,145,638		$	2,645,715		$	2,499,923
	Know How	15			512,000			179,283			332,717
	Trade Names	15 or Indefinite			547,802			75,856			471,946
	Biomedical Technologies	5			300,000			120,003			179,997
				$	6,505,440		$	3,020,857		$	3,484,583
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	'
	Amortization expense for the three months ended December 31, 2013 and 2012 was $44,888 and $181,268, respectively.  Estimated amortization expense for each of the next five fiscal years is as follows:
		2014			2015			2016			2017		2018		Thereafter		Total
	Acquired Customer Base	$	59,964		$	79,952		$	79,952		$	79,952	$	79,952	$	148,644	$	528,416
	Know How		25,596			34,128			34,128			34,128		34,128		162,077		324,185
	Biomedical Technologies		50,000			66,667			46,666			-		-		-		163,333
		$	135,560		$	180,747		$	160,746		$	114,080	$	114,080	$	310,721	$	1,015,934

Earnings_Loss_Per_Common_Share1

Earnings (Loss) Per Common Share (Tables)	3 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
	The computation of the weighted shares outstanding for the three months ended December 31 is as follows:
		December 31, 2013		December 31, 2012
	Weighted average shares outstanding
	Basic		15,021,757		14,673,356
	Effect of dilutive securities
	Stock Options		-		-
	Restricted Stock		260,084		-
	Dilutive Average Shares Outstanding		15,281,841		14,673,356

Stock_Based_Compensation_Table

Stock Based Compensation (Tables)	3 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	'
	A summary of stock option activity for the three months ended December 31, 2013 and 2012 is presented below:
				Weighted Average		Weighted Average
		Options		Exercise Price per		Remain Contractual
		Outstanding		Share		Term (in Years)
	Balance at September 30, 2013		630,532	$	3.33	1.06
	Outstanding and exercisable at September 30, 2013		630,532	$	3.33	1.06
	Granted		-		-
	Exercised		-		-
	Cancelled		-		-
	Balance at December 31, 2013		630,532	$	3.33	0.81
	Outstanding and exercisable at December 31, 2013		630,532	$	3.33	0.81
				Weighted Average		Weighted Average
		Options		Exercise Price per		Remain Contractual
		Outstanding		Share		Term (in Years)
	Balance at September 30, 2012		794,483	$	3.34	1.75
	Outstanding and exercisable at September 30, 2012		794,483	$	3.34	1.75
	Granted		-		-
	Exercised		-		-
	Cancelled		-20,000	$	4.06
	Balance at December 31, 2012		774,483	$	3.32	1.54
	Outstanding and exercisable at December 31, 2012		774,483	$	3.32	1.54
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	'
	A summary of restricted stock activity for the three months ended December 31, 2013 and 2012 is presented below:
	Restricted Stock Activity for the Three			Weighted-Average
	Months ended December 31, 2013	Shares		Grant-Date Fair Value
	Nonvested at September 30, 2013		423,168	$	0.74
	Granted		-	$	-
	Vested		-12,500	$	1.08
	Cancelled		-	$	-
	Nonvested at December 31, 2013		410,668	$	0.73
	Restricted Stock Activity for the Three			Weighted-Average
	Months ended December 31, 2012	Shares		Grant-Date Fair Value
	Nonvested at September 30, 2012		127,834	$	1.92
	Granted		4,000	$	1.45
	Vested		-15,000	$	1.53
	Cancelled		-	$	-
	Nonvested at December 31, 2012		116,834	$	1.95
Schedule Of Stock Compensation Expense [Table Text Block]	'
	Stock Compensation Expense for the three months ended December 31, 2013 and 2012 is as follows:
		Three Months Ended		Three Months Ended
	Stock Compensation Expense	December 31, 2013		December 31, 2012
	Stock Grants	$	50,626	$	52,461
	Restricted Stock Grants		68,351		12,618
	Option Grants		-		7,359
	Employee Stock Purchase Plan		669		1,078
	Total	$	119,646	$	73,516

Segment_Customer_and_Geographi1

Segment, Customer and Geographical Reporting (Tables)	3 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'
	The Company’s segment information for the three months ended December 31, 2013 and 2012 is summarized below:
	Results of Operations for the Three Months Ended December 31,
	2013
		Contract
		Research		Optics		Instruments		Biomedical		Total
	Revenue	$	5,840,442	$	4,098,508	$	772,578	$	-	$	10,711,528
	Gross Profit		2,529,539		1,597,259		323,730		-		4,450,528
	Operating Income (Loss)		348,394		398,428		1,041,768		-174,372		1,614,218
	Depreciation and Amortization		69,547		178,108		2,003		16,667		266,325
	Capital expenditures		-		130,918		-		-		130,918
	Intangibles, Net		324,185		869,974		-		163,333		1,357,492
	Goodwill		4,938,625		1,317,698		-		-		6,256,323
	Total Assets	$	10,359,612	$	12,538,356	$	752,431	$	504,904	$	24,155,303
	Results of Operations for the Three Months Ended December 31,
	2012
		Contract
		Research		Optics		Instruments		Biomedical		Total
	Revenue	$	4,910,840	$	4,251,940	$	1,284,038	$	106,457	$	10,553,275
	Gross Profit		2,214,053		1,700,555		605,801		106,457		4,626,866
	Operating Income (Loss)		-606		385,676		-455,694		-120,663		-191,287
	Depreciation and Amortization		62,782		185,628		163,048		15,000		426,458
	Capital expenditures		186,330		122,146		7,092		-		315,568
	Intangibles, Net		339,886		946,525		5,016,201		224,996		6,527,608
	Goodwill		4,938,625		1,310,802		4,015,072		-		10,264,499
	Total Assets	$	13,290,669	$	10,607,828	$	12,092,507	$	388,671	$	36,379,675
Schedule Of Segment Revenue By Geographical Location [Table Text Block]	'
	Revenue by geographic location in total and as a percentage of total revenue, for the three months ended December 31, 2013 and 2012 are as follows:
		Three Months Ended				Three Months Ended
		December 31, 2013				December 31, 2012
	Geographic Location	Revenue		% of Total		Revenue		% of Total
	United States	$	8,907,730	83	%	$	8,494,488	81	%
	Europe		829,437	8	%		888,341	8	%
	Other		974,361	9	%		1,170,446	11	%
		$	10,711,528	100	%	$	10,553,275	100	%

Basis_of_Presentation_and_Abil1

Basis of Presentation and Ability to Continue as a Going Concern (Details Textual) (USD $)	3 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Dec. 31, 2012
Basis Of Presentation [Line Items]	'	'	'
Debt Instrument, Increase, Accrued Interest	$400,000	'	'
Debt Instrument, Periodic Payment, Principal	3,900,000	300,000	'
Long-term Debt, Current Maturities, Total	$5,429,762	$9,819,048	$11,500,000

Businesses_Sold_Details_Textua

Businesses Sold (Details Textual) (USD $)	3 Months Ended		1 Months Ended	0 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Dec. 23, 2013	Nov. 07, 2013
			Gamma Medical Probe [Member]	Lead Paint detector [Member]
Businesses Sold [Line Items]	'	'	'	'
Proceeds from Divestiture of Businesses	'	'	$3,500,000	$1,200,000
Proceeds from Customers	'	'	'	500,000
Repayments of Bank Debt	'	'	2,750,000	1,175,000
Escrow Deposit	'	'	250,000	'
Gain (Loss) on Disposition of Business	1,200,000	'	'	'
Assets Held-for-sale, at Carrying Value, Total	'	2,900,000	'	'
Customer Deposits, Noncurrent	'	$100,000	'	'

Formation_of컞Technologie1

Formation of Xcede Technologies, Inc. Joint Venture (Details Textual) (USD $)	0 Months Ended
	Oct. 02, 2013
Schedule of Equity Method Investments [Line Items]	'
Proceeds from Convertible Debt	$400,000
Debt Instrument, Interest Rate, Stated Percentage	5.00%
Capital Stock Financing Discount Percentage	20.00%
Common Stock Valuation	$5,000,000
Equity Method Investment, Ownership Percentage	90.00%
Common Stock, Conversion Features	'at any time prior to a capital stock financing the note holders can convert at their option into common stock based on a $5 million valuation.

Inventories_Details

Inventories (Details) (USD $)	Dec. 31, 2013	Sep. 30, 2013
Inventory Current [Line Items]	'	'
Raw Materials	$1,713,898	$2,132,962
Work-in-Process	717,888	703,873
Finished Goods	246,738	303,409
Inventory, Net, Total	$2,678,524	$3,140,244

Intangible_Assets_Details

Intangible Assets (Details) (USD $)

Dec. 31, 2013

Sep. 30, 2013

Dec. 31, 2012

Dec. 31, 2013

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Acquired Customer Base [Member]

Acquired Customer Base [Member]

Acquired Customer Base [Member]

Acquired Customer Base [Member]

Acquired Customer Base [Member]

Acquired Customer Base [Member]

Know How [Member]

Know How [Member]

Trade Names [Member]

Trade Names [Member]

Biomedical Technologies [Member]

Biomedical Technologies [Member]

Biomedical Technologies [Member]

Biomedical Technologies [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Finite-Lived Intangible Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Useful Life (years)

'

'

'

'

'

'5 years

'5 years

'15 years

'15 years

'15 years

'15 years

'15 years

'

'5 years

'

'2 years 3 months

'5 years

Gross Amount

$1,994,633

$6,505,440

'

$881,075

$5,145,638

'

'

'

'

$512,000

$512,000

$547,802

$341,558

$300,000

$260,000

'

'

Accumulated Amortization

637,141

3,020,857

'

352,659

2,645,715

'

'

'

'

187,815

179,283

75,856

0

120,003

96,667

'

'

Net

$1,357,492

$3,484,583

$6,527,608

$528,416

$2,499,923

'

'

'

'

$324,185

$332,717

$471,946

$341,558

$179,997

$163,333

'

'

Intangible_Assets_Details_1

Intangible Assets (Details 1) (USD $)	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]	'
2014	$135,560
2015	180,747
2016	160,746
2017	114,080
2018	114,080
Thereafter	310,721
Total	1,015,934
Acquired Customer Base [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
2014	59,964
2015	79,952
2016	79,952
2017	79,952
2018	79,952
Thereafter	148,644
Total	528,416
Know How [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
2014	25,596
2015	34,128
2016	34,128
2017	34,128
2018	34,128
Thereafter	162,077
Total	324,185
Biomedical Technologies [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
2014	50,000
2015	66,667
2016	46,666
2017	0
2018	0
Thereafter	0
Total	$163,333

Intangible_Assets_Details_Text

Intangible Assets (Details Textual) (USD $)	3 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization of Intangible Assets	$44,888	$181,268

Earnings_Loss_Per_Common_Share2

Earnings (Loss) Per Common Share (Details)	3 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Weighted average shares outstanding	'	'
Basic	15,021,757	14,673,356
Effect of dilutive securities	'	'
Dilutive Average Shares Outstanding	15,281,841	14,673,356
Stock Option [Member]	'	'
Effect of dilutive securities	'	'
Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements	0	0
Restricted Stock [Member]	'	'
Effect of dilutive securities	'	'
Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements	260,084	0

Earnings_Loss_Per_Common_Share3

Earnings (Loss) Per Common Share (Details Textual)	3 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Earnings Loss Per Common Share [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	630,532	774,483

Stock_Based_Compensation_Detai

Stock Based Compensation (Details) (USD $)	3 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Balance,Options Outstanding	630,532	'	794,483	'
Outstanding and exercisable,Options	630,532	'	794,483	'
Granted,Options Outstanding	0	'	0	'
Exercised,Options Outstanding	0	'	0	'
Cancelled, Options Outstanding	0	'	-20,000	'
Balance,Options Outstanding	630,532	630,532	774,483	794,483
Outstanding and exercisable,Options	630,532	630,532	774,483	794,483
Balance,Weighted Average Exercise Price per Share	$3.33	'	$3.34	'
Outstanding and exercisable,Weighted Average Exercise Price per Share	$3.33	'	$3.34	'
Granted,Weighted Average Exercise Price per Share	$0	'	$0	'
Exercised,Weighted Average Exercise Price per Share	$0	'	$0	'
Cancelled,Weighted Average Exercise Price per Share	$0	'	$4.06	'
Balance,Weighted Average Exercise Price per Share	$3.33	$3.33	$3.32	$3.34
Outstanding and exercisable,Weighted Average Exercise Price per Share	$3.33	$3.33	$3.32	$3.34
Balance,Weighted Average Remain Contractual Term (In Years)	'9 months 22 days	'1 year 22 days	'1 year 6 months 14 days	'1 year 9 months
Outstanding and exercisable options,Weighted Average Remain Contractual Term (In Years)	'9 months 22 days	'1 year 22 days	'1 year 6 months 14 days	'1 year 9 months

Stock_Based_Compensation_Detai1

Stock Based Compensation (Details 1) (USD $)	3 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Shares Nonvested, Beginning Balance	423,168	127,834
Shares, Granted	0	4,000
Shares, Vested	-12,500	-15,000
Shares, Cancelled	0	0
Shares, Nonvested, Ending Balance	410,668	116,834
Weighted-Average Grant-Date Fair Value, Nonvested, Beginning Balance	$0.74	$1.92
Weighted-Average Grant-Date Fair Value, Granted	$0	$1.45
Weighted-Average Grant-Date Fair Value, Vested	$1.08	$1.53
Weighted-Average Grant-Date Fair Value, Cancelled	$0	$0
Weighted-Average Grant-Date Fair Value, Nonvested, Ending Balance	$0.73	$1.95

Stock_Based_Compensation_Detai2

Stock Based Compensation (Details 2) (USD $)	3 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Stock Based Compensation [Line Items]	'	'
Stock Compensation Expense	$119,646	$73,516
Stock Grants [Member]	'	'
Stock Based Compensation [Line Items]	'	'
Stock Compensation Expense	50,626	52,461
Restricted Stock Grants [Member]	'	'
Stock Based Compensation [Line Items]	'	'
Stock Compensation Expense	68,351	12,618
Option Grants [Member]	'	'
Stock Based Compensation [Line Items]	'	'
Stock Compensation Expense	0	7,359
Employee Stock Purchase Plan [Member]	'	'
Stock Based Compensation [Line Items]	'	'
Stock Compensation Expense	$669	$1,078

Stock_Based_Compensation_Detai3

Stock Based Compensation (Details Textual) (USD $)	3 Months Ended
	Dec. 31, 2013
Stock Based Compensation [Line Items]	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$170,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	'5 months

Segment_Customer_and_Geographi2

Segment, Customer and Geographical Reporting (Details) (USD $)	3 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Sep. 30, 2013
Segment Reporting Information [Line Items]	'	'	'
Revenue	$10,711,528	$10,553,275	'
Gross Profit	4,450,528	4,626,866	'
Operating Income (Loss)	1,614,218	-191,287	'
Depreciation and Amortization	266,325	426,458	'
Capital expenditures	130,918	315,568	'
Intangibles, Net	1,357,492	6,527,608	3,484,583
Goodwill	6,256,323	10,264,499	6,240,983
Total Assets	24,155,303	36,379,675	26,677,226
Contract Research [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Revenue	5,840,442	4,910,840	'
Gross Profit	2,529,539	2,214,053	'
Operating Income (Loss)	348,394	-606	'
Depreciation and Amortization	69,547	62,782	'
Capital expenditures	0	186,330	'
Intangibles, Net	324,185	339,886	'
Goodwill	4,938,625	4,938,625	'
Total Assets	10,359,612	13,290,669	'
Optics [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Revenue	4,098,508	4,251,940	'
Gross Profit	1,597,259	1,700,555	'
Operating Income (Loss)	398,428	385,676	'
Depreciation and Amortization	178,108	185,628	'
Capital expenditures	130,918	122,146	'
Intangibles, Net	869,974	946,525	'
Goodwill	1,317,698	1,310,802	'
Total Assets	12,538,356	10,607,828	'
Instruments [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Revenue	772,578	1,284,038	'
Gross Profit	323,730	605,801	'
Operating Income (Loss)	1,041,768	-455,694	'
Depreciation and Amortization	2,003	163,048	'
Capital expenditures	0	7,092	'
Intangibles, Net	0	5,016,201	'
Goodwill	0	4,015,072	'
Total Assets	752,431	12,092,507	'
Biomedical [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Revenue	0	106,457	'
Gross Profit	0	106,457	'
Operating Income (Loss)	-174,372	-120,663	'
Depreciation and Amortization	16,667	15,000	'
Capital expenditures	0	0	'
Intangibles, Net	163,333	224,996	'
Goodwill	0	0	'
Total Assets	$504,904	$388,671	'

Segment_Customer_and_Geographi3

Segment, Customer and Geographical Reporting (Details 1) (USD $)	3 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Revenue	$10,711,528	$10,553,275
% of Total	100.00%	100.00%
United State [Member]	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Revenue	8,907,730	8,494,488
% of Total	83.00%	81.00%
Europe [Member]	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Revenue	829,437	888,341
% of Total	8.00%	8.00%
Other Credit Derivatives [Member]	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Revenue	$974,361	$1,170,446
% of Total	9.00%	11.00%

Segment_Customer_and_Geographi4

Segment, Customer and Geographical Reporting (Details Textual)	3 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Optics [Member]	'	'
Segment Reporting [Line Items]	'	'
Concentration Risk, Percentage	10.00%	10.00%
Instrument Segment [Member]	'	'
Segment Reporting [Line Items]	'	'
Concentration Risk, Percentage	24.00%	40.00%
Biomedical Technologies [Member] | Sales [Member]	'	'
Segment Reporting [Line Items]	'	'
Concentration Risk, Percentage	0.00%	100.00%
Contract Research [Member]	'	'
Segment Reporting [Line Items]	'	'
Concentration Risk, Percentage	64.00%	68.00%

Income_Taxes_Details_Textual

Income Taxes (Details Textual)	3 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Tax [Line Items]	'	'
Effective Income Tax Rate Reconciliation, Percent, Total	3.12%	0.34%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	34.00%	'